Crossbow Therapeutics, Inc.
3 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 6 directorsboard
6 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
Financing history
- Sep 17, 2025Form D equity offering · $30.3M (form d sold) · 17 investorsFact Form D · “Crossbow Therapeutics, Inc. filed Form D: $30,250,000 sold of $80,000,000, Biotechnology”
Who would invest
How comparable investors are foundComparable investors backed two or more of the companies this company’s own investors also back. Broader fit co-invested two or more times with them and dated a new company in the last 12 months. Each reason is a fact on record: a shared company, a co-investment count, a dated deal, a stage or round size it has joined. A shared sector alone never puts a firm here. Nothing is a prediction that a firm will invest.Already invested
1 investor on record- MPM Bioimpact board only, Todd Foley (strongly supported) Inference sec.gov
Strong comparable investors
1 firmFirms that backed two or more of the companies this company's own investors also back.
- NEA: New Enterprise Associates
- Backed 3 companies this company's investors also back
- Co-invested 4 times with 1 of this company's investors
- Has joined rounds of $15M to $50M (19 on record)
- Invests in Life sciences
- No new company dated in 12 months; latest deal Dec 16, 2025
Broader fit
0 firmsFirms that co-invest repeatedly with this company's investors and dated a new company in the last 12 months.
No other firm co-invests repeatedly with this company's investors on record.
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.No firm portfolio page lists this company, so no outcome is stated.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Alexander Nolte Executive Officer sec.gov
- Briggs Morrison Executive Officer/Director/Promoter sec.gov
- Dmitri Wiederschain Executive Officer sec.gov
- Alexandra Cantley Director Fact
- Sakae Asanuma Director Fact
Show all 6 officers and directors
- Alexander Nolte Executive Officer sec.gov
- Briggs Morrison Executive Officer/Director/Promoter sec.gov
- Dmitri Wiederschain Executive Officer sec.gov
- Alexandra Cantley Director Fact
- Sakae Asanuma Director Fact
- Charles Baum Director Fact
Timeline
- Sep 30, 2025Crossbow Therapeutics, Inc. filed Form D: $30,250,000 sold of $80,000,000, BiotechnologyForm D filed Fact Form D
Evidence
Every observation on this company
- Entity type: Corporation Sep 30, 2025 Fact Form D
- Form D industry group: Biotechnology Sep 30, 2025 Fact Form D
- Amendment: false Sep 30, 2025 Fact Form D
- Revenue range (Form D): Decline to Disclose Sep 30, 2025 Fact Form D
- Incorporated: withinFiveYears Sep 30, 2025 Fact Form D
- Jurisdiction: Delaware Sep 30, 2025 Fact Form D
- Amount sold (Form D): $30.3M Sep 30, 2025 Fact Form D
- Offering amount (Form D): $80.0M Sep 30, 2025 Fact Form D
- Exemptions: 06b Sep 30, 2025 Fact Form D
- First sale: 2025-09-17 Sep 30, 2025 Fact Form D
- Investors (Form D): 17 Sep 30, 2025 Fact Form D
- Minimum investment (Form D): 0 Sep 30, 2025 Fact Form D
- Securities offered: equity Sep 30, 2025 Fact Form D
- Office address: Sep 30, 2025 Fact Form D
- Year of incorporation: 2021 Sep 30, 2025 Fact Form D
Relationships across DFX
on 1 other DFX graph
Crossbow Therapeutics, Inc. is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Form D filed2025-09-30source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.